Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells

Blood

Volumn 120, Issue 15, 2012, Pages 3098-3105

  Lu, Min ^a   Wang, Xiaoli ^a   Li, Yan ^a   Tripodi, Joseph ^a   Mosoyan, Goar ^a   Mascarenhas, John ^a   Kremyanskaya, Marina ^a   Najfeld, Vesna ^a   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; NUTLIN 1; PEGINTERFERON ALPHA2A; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; STAT1 PROTEIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 84867750834     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-410712     Document Type: Article

References (43)

1. Hoffman R, Xu M, Finazzi G, Barbui T. The polycythemias. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds, Hematology: Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone; 2008:1073-1108.
2. Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev. 2005;19(1):1-13. (Pubitemid 39574245)
3. Mesa RA. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int J Hematol. 2002;76(Suppl 2):193-203.
4. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272-4290. (Pubitemid 35429665)
5. Lucet IS, Fantino E, Styles M, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 2006;107(1):176-183. (Pubitemid 43053540)
6. Williams NK, Bamert RS, Patel O, et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol. 2009;387(1):219-232.
7. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009;16(6):487-497.
8. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009;23(8):1441-1445.
9. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010;115(25):5232-5240.
10. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor in myelofibrosis. N. Engl J Med. 2010;363(12):1117-1127.
11. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-796.
12. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 2011;25(5):229-237.
13. Atallah E, Verstovsek S. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms [review]. Expert Rev Anticancer Ther. 2009;9(5):663-670.
14. Messora C, Bensi L, Vecchi A, et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol. 1994;86(2):402-404. (Pubitemid 24199014)
15. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108(6):2037-2040. (Pubitemid 44395018)
16. Kiladjian JJ, Cassinat B, Chevret S, et al., Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072.
17. Kiladjian J-J, Chomienne C, Fenaux P. Interferonalpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22(11):1990-1998.
18. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006;107(3):451-458. (Pubitemid 44107203)
19. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem. 2007;282(28):20053-20057. (Pubitemid 47099976)
20. Lu M, Zhang W, Berenzon D, et al. Interferonalpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol. 2010;38(6):472-480.
21. De Amicis F, Giordano F, Vivacqua A, et al. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 2011;25(10):3695-3707.
22. Lamy V, Bousserouel S, Gossé F, Minker C, Lobstein A, Raul F. Lupulone triggers p38 MAPK-controlled activation of p53 and of the TRAIL receptor apoptotic pathway in human colon cancerderived metastatic cells. Oncol Rep. 2011;26(1):109-114.
23. Li Y, Matsumori H, Nakayama Y, et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells. 2011;16(1):34-45.
24. Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci U S A. 1991;88(14):6293-6297. (Pubitemid 21914932)
25. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat. 1999;14(1):1-8. (Pubitemid 29309938)
26. Tsurumi S, Nakamura Y, Maki K, et al. N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol. 2002;71(2):131-133.
27. Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011;364(5):488-490.
28. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13(1):23-31. (Pubitemid 46027725)
29. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844-848. (Pubitemid 38174664)
30. Nakatake M, Monte-Mor B, Debili N, et al JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31(10):1323-1333.
31. Andreeff M, Kojima K, Padmanabhan S, et al. A multi-center, open-label, phase I study of single agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL). Blood. 2010;116:657.
32. Shadduck RK, Gilmore GL, Lister J. Role of serum-free medium in the ex vivo expansion of human cord blood hematopoietic stem cells. Stem Cells. 2000;18(2):154-155.
33. Ivanovic Z, Duchez P, Chevaleyre J. Clinical-scale cultures of cord blood CD34(+) cells to amplify committed progenitors and maintain stem cell activity. Cell Transplant. 2011;20(9):1453-1463.
34. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108(9):3128-3134.
35. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science. 1996;272(5262):719-722.
36. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A. 1996;93(15):7673-7678. (Pubitemid 26277095)
37. Stephanou A, Latchman DS. STAT-1: a novel regulator of apoptosis. Int J Exp Pathol. 2003; 84(6):239-244. (Pubitemid 38221802)
38. Arulampalam V, Kolosenko I, Hjortsberg L, Björklund AC, Grandér D, Tamm KP. Activation of STAT1 is required for interferon-alpha-mediated cell death. Exp Cell Res. 2011;317(1):9-19.
39. Townsend PA, Scarabelli TM, Davidson SM, et al. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 2004;279(7):5811-5820. (Pubitemid 38220612)
40. Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal. 2007;19(3):454-465. (Pubitemid 46107818)
41. Youlyouz-Marfak I, Gachard N, Le Clorennec C, et al. Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ. 2008;15(2):376-385.
42. Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther. 2011;10(1):69-79.
43. Marine JC. MDM2 and MDMX in cancer and development. Curr Top Dev Biol. 2011;94:45-75.